Ziopharm gets hit with a clinical hold as FDA red lights human study using their fast-built CAR-T

One of Ziopharm’s $ZIO heavily touted, fast-built CAR-Ts isn’t ready for a human trial just yet. The biotech reports that the FDA has dropped a clinical hold on their Phase I study of a CAR-T that can be built in 2 days to express CD-19, IL-15 and a safety switch for CD-19/positive leukemias and lymphomas.